I am the MedSci AI Translation Assistant. Please provide the content you need translated.
Summary of the study results: This meta-analysis pooled safety data from 16 clinical trials (including single-arm and RCTs) to analyze the toxicity profiles of different Trop2-ADC drugs. Additionally, a network meta-analysis was conducted based on RCT data. The results showed that Dato-DXd ranked high in terms of overall safety among Trop2-ADC drugs (including grade 3 or higher TRAEs, TRAEs leading to death, and grade 3 or higher hematological toxicities). In non-hematological toxicities of concern for Trop2-ADCs, the incidence of grade 3 or higher stomatitis with Dato-DXd was lower than that of SKB264, but it performed worse than SG in gastrointestinal adverse events (such as nausea and vomiting). SKB264 ranked lower than SG in terms of safety regarding elevated transaminases. In efficacy analysis, Dato-DXd had better ORR and PFS rankings for treating HR+/HER2- advanced breast cancer compared to SG, although its ranking in OS analysis was lower due to data maturity issues. In advanced TNBC, SG's overall ranking was better than SKB264.
